Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC

Introduction: We present the results of a phase 2a trial of first-line avelumab (anti–programmed death-ligand 1 antibody) plus cetuximab (anti–EGFR antibody) in patients with advanced squamous NSCLC. Methods: Patients with recurrent or metastatic squamous NSCLC received avelumab 800 mg (d 1 and 8),...

Full description

Bibliographic Details
Main Authors: Zoran Andric, MD, Gabriella Gálffy, MD, Manuel Cobo Dols, MD, Barna Szima, MD, Goran Stojanovic, MD, Marina Petrovic, MD, Enriqueta Felip, MD, David Vicente Baz, MD, Santiago Ponce Aix, MD, Oscar Juan-Vidal, MD, Zsuzsanna Szalai, MD, Gyorgy Losonczy, MD, Antonio Calles Blanco, MD, Reyes Bernabe, MD, Gema García Ledo, MD, Andrés Aguilar Hernández, MD, Klaus Duecker, PhD, Dongli Zhou, PhD, Andreas Schroeder, MD, Guelseren Guezel, MD, Fortunato Ciardiello, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-02-01
Series:JTO Clinical and Research Reports
Subjects:
Avelumab
Cetuximab
PD-L1
EGFR
Non–small cell lung cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001862

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001862

Similar Items